ViaDerma Inc. (VDRM) Stock Message Board

Moderator: fly_fisherman, slops, Shift-4, vegasandre, HNDRXX, limitlessotc

Search This Board:

Last Post: 2/25/2021 9:25:51 PM - Followers: 582 - Board type: Free - Posts Today: 52

VDRM

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE
VITASTEM

Available at .... https://www.vitastem.net

ViaDerma Licensing FaceBook page at... https://www.facebook.com/ViaDermaInc

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________

https://www.vitastem.net/pages/before-afters

https://www.vitastem.net/products/vitastem

Vitastem treats Acne, Burns, Eczema, Infections, Psoriasis and Wounds

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
Estimated Global prevalence rate of MRSA: 140 million.

Topical Toenail Antifungal
Acne
Psoriasis
Eczema

Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

Estimated Global prevalence rate of Influenza: 355-1065 million.
Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009

Wound care

Diabetic foot wounds.

Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744

Email: info@viadermalicensing.com

VDRM CBD PATENT UPDATES

CBD Product launch!!!

Initial order of 1,000 units sold into Canada have SOLD OUT!

https://elixrcannabis.com/

Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.

Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.

Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.

What is CBD

CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.

CBD in Skin Care

CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.

Dual Carrier Technology

Developed by a British Doctor and an American Pharmaceutical Company. Our Topical Products are formulated using Viaderma Pharmaceutical's Patent Pending Dual Carrier Technology. CBD is formulated into the carrier solution. This solution is then mixed with the professionally crafted skin care product using critically Essential Oils to maximize skin health care regime.

Elixr Hemp CBD Product Line

Our Elixr Hemp CBD Product line has a CBD Absorption Rate of 92% powered by Viaderma Pharmaceutical’s Patent Pending Dual Carrier Technology. Elixr Cannabis has the exclusive global rights to this groundbreaking technology combined with any Cannabinoids. Our products are second to none due to this independent laboratory tested high absorption rate combined with Elixr’s CDB profile.

Our CBD and Terpene profile, enriched with specific Essential Oils, Vitamin C, and Vitamin D, is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. CBD is known to have Anti-Inflammatory, Anti-Oxidant, and Anti-Aging properties that absorbs into the skin and provides overall healing benefits.

All our products are proudly Cruelty-free, 100% Toxin-free, Sodium Lauryl Sulfate free, Phthalate free, Parabens free, Petrochemicals free, Triclosan-free, Diethanolamine free and best of all, are handcrafted in Victoria, BC.

Essential Oils of Cypress, Frankincense, and Geranium

Essential Oils of Mint and Van

Topical S

Essential Oils of Lavender and Yarr

"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
PATENTS			TRADEMARKS
NAME	NUMBER	NOTES	NAME	NUMBER	STATUS
2014 Provisional TBD	TBD	Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here.	BIOGENX	87290961	641 - Non-Final Action
2016 Patent App TBD	TBD	"its proprietary innovative transdermal delivery system"	VITASTEM	87227123	681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent" (Incorrect Term)	62466209	Was this filed to replace the expired provisional cannabis app from 2014?
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses"	62433964	Is this related to the Viabecline product developed by the Phillips Company using their patent?

VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name	Owner	Registered	Otiko's Role
BIOGENX 19772 Trident Lane Huntington Beach, CA 92646	Garrett Adams	NV First registered 12.14.16	Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd	TBD	No result from search in Canada, England & India	TBD
Coast to Coast Podiatry, Inc. 6648 Reseda Blvd Reseda, CA 91335	TBD	CA First Registered 06.14.11 Updated 07.13.16	Otiko states he is "Minority Owner" in his 12.09.16 Video Interview. He is the named CEO, CFO, Secretary. He was also sole director until filing of July 2016. Sole Director is now his wife, Ekaterina Otiko. Is Ekaterina the majority owner? NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.

======================================================================================================

A Note From The CEO

Date: June 25, 2018

Dear Shareholders & Associates of ViaDerma,

What exciting times we are in as ViaDerma continues to make big strides both domestically and internationally. As we continue such an expansion I want to ensure that you remain abreast of all developments and changes as they occur. This note is just the first of many to come as I am committing to you, our most valued shareholder to address you on a regular basis. Upon your receipt of this and every future note I encourage you to ask questions and learn more about what ViaDerma embarks upon to ensure that the union of our company, both present and future remains strong.

Since the start of 2018, ViaDerma has achieved several new milestones and I believe we are now poised to experience very significant growth in the coming months. While we feel our current trajectory is pointed upward, the last year has not been without its challenges. Fortunately, the bumps along the way have been minor in the big scheme of things, and resolvable and have only caused temporary delays in our progress. Below is a list of some of the key developments and setbacks we have experienced so far:

• Our recent trip to India was a great success. I was able to personally demonstrate the effectiveness of our product and meet with several potential future partners who are interested in distributing Vitastem. We are in the process of follow up discussions with three of them, and hope to introduce Vitastem into the Indian market in the very near future.

• The process of registering Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA was initiated last month. Registration is expected to be finalized in July. At that time, Vage Nigeria Ltd. will pay a 50% deposit to ViaDerma in the amount of $125,000 for its initial order worth $250,000.

• Over the past several weeks I have been meeting with representatives for a South American based distributor. As per our discussions thus far, I expect to receive their initial order for Vitastem within the next few weeks. They have indicated an interest in purchasing lots of 200,000 per month. An order of that size would equal $3 million in annual revenues.

• Sales in Japan are temporarily held up while some issues are being resolved. At the customer’s request we will be changing the active ingredient of the antibiotic for their orders from tetracycline to a natural product, Manuka Honey UMF-15. Once the changes have been worked out we expect to commence a steady flow of product delivery to our Japanese distributors.

• Drug registration in the Philippines has taken much longer than originally anticipated and is not expected to be completed until later this year. We are working closely with regulators to move the process forward.

• Vitastem has been available for purchase on Amazon for the past few months. In the brief time on Amazon, sales have been growing each month at a very strong rate with minimal marketing efforts to this point. May sales grew by 67%, and we anticipate being on Amazon

Prime in the coming weeks which should dramatically increase our sales. We will be rolling out an aggressive product marketing campaign in the near future which we expect will result in a significant increase in sales on Amazon and across other platforms.

• We have recently produced the first in a series of commercials advertising Vitastem and showcasing the product’s versatility. The initial ad presented the product as a household staple for treating minor cuts and scrapes. The next ad in the series will focus on Vitastem’s ability to heal diabetic wounds and major skin conditions. We are in the process of selecting strategic outlets to broadcast the commercials and promote the product to key demographic audiences.

• Prolayed is ready to go. Development has been completed and it is now an official FDA registered product. It will be introduced into the same sales channels as Vitastem as well as other products we will be introducing in the future.

• We have initiated the process of registering Vitastem for medical insurance coverage. The response so far has been very favorable and the expectation is to have final approved for insurance payments and reimbursements for January 2019.

• We are also in discussions with a company that provides services to over 600 Skilled Nursing Facilities in California to use Vitastem in their Wound Care Program.

• Our initial CBD sales of Elixr in Canada was a success and sold out completely. As a result of that success we were recently contacted by a publicly traded Cannabis product company based in Colorado about producing a line of CBD products for sales in the U.S.. We are currently in discussions with them and exploring all options. We are now evaluating our next move with regard to domestic CBD sales as opposed to relaunching a broader campaign in Canada. CBD sales in Canada face far more stringent regulatory obstacles than CBD sales in the U.S. The more favorable logistics of domestic sales vs foreign sales would also increase the bottom line significantly.

In addition to these developments, we are working diligently on many other important initiatives aimed at making our company a major player in our industry. We are constantly seeking out new partners and distributors to keep moving ViaDerma forward and expanding the sales of our products. Admittedly things have not always happened in the timeframes hoped for, but I am confident we are getting very close to moving our Company to the next level. However, as we focus on growing the business we never lose sight of our most important mission to help each and every one of our customers improve their quality of life. Nothing is more gratifying for me then hearing so many success stories from Vitastem users, and how our product has changed their life. That is the reason we get up every morning and continue to fight on so we can make a difference in people’s lives. The more people we can help the more successful we will be as a company and as individual shareholders. Please continue to send us your stories. We love to hear from you.
Sincerely,
Dr. Chris Otiko President and CEO

=========================================================================================================================================================

RECENT NEWS

01/1/2020 VDRM corporate update https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Provides-a-Corporate-Update?id=251402

7/12/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Provides-an-Update-to-Shareholders-via-a-Letter-from-the-CEO?id=197800

5/29/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Announces-Increase-of-Amazon-Sales-on-the-Heels-of-US-Department-of-Commerce-Trade-Mission-to-India?id=193748

5/18/18 - https://backend.otcmarkets.com/otcapi/company/financial-report/193710/content

5/15/18 - https://www.otcmarkets.com/stock/VDRM/news/United-States-Commerce-Department-Invites-ViaDerma-to-Participate-in-Official-Trade-Mission-to-India?id=192363

4/24/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Enters-into-a-250000-Initial-Sales-Agreement-with-Vage-Nigeria-Ltd?id=190023

4/2/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Provides-an-Update-of-Current-and-Future-Product-Sales?id=187805

3/8/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Provides-an-Update-of-Current-Marketing-Activities?id=185519

3/2/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Refutes-the-Recent-Announcement-by-Kasten-Inc?id=184989

2/26/18 - https://www.otcmarkets.com/stock/VDRM/news/US-District-Court-Rules-Favorably-for-Kasten-Inc-on-Basis-of-Legal-Allegations-Against-Defendants-Viaderma-Otiko-and-Phi?id=184428

2/6/18 - http://www.marketwired.com/press-release/lawsuit-against-viaderma-inc-has-been-dismissed-us-district-federal-court-as-company-otc-pink-vdrm-2245474.htm

1/23/18 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma--Inc--Announces-Plan-to-Target-Licensed-Dispensaries-in-California-after-State-Legalizes-Recreational-Marijuana--amp--Seeks-Reimbursement-from-Insurance-Companies-for-its-FDA-Registered-Topical-Antibiotic-Products?id=181110&b=y

12/7/17 - https://www.otcmarkets.com/stock/VDRM/news/ViaDerma--Inc--Looks-to-have-Sales-Representatives-Selling-its-FDA-Registered-Medication-VitaStem-to-a-Network-of-1000-Physician-Offices-Nationwide-in-2018?id=177510&b=y

11/21/17 - ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products

10/19/17 - ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx

09/08/17 - ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada

08/18/2017 - ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

06/27/2017- Viaderma, Inc Receives National Drug Code (NDC) from the FDA for Prolayed, It's New OTC Drug for Premature Ejaculation For Men

06/12/17 - ViaDerma, Inc. Commences First Manufacturing Run And Will Meet the 2nd Quarter Product Distribution Milestone

05/15/17 - Viaderma, Inc. Recevies Positive Results On Phase I Testing In Canada With Its Proprietary THC delivery and moves to Phase II Trials and Development Of New Products With Its MMJ Technologies

05/03/17 - ViaDerma, Inc. Will Vigorously Defend The Company's Patents, Product Line, and its Shareholders from current complaint against the company

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes

02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also Onychomycosis Clinical Studies Show Significant Results

01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017

12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

www.facebook.com/ViaDermaInc

VDRM
Current Price
Volume:

Bid	Ask	Day's Range


VDRM Detailed Quote

ViaDerma Inc. (VDRM)

VDRM

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.